Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Alzheimers Disease: early-phase trial registry
30 of 145 indexed Alzheimers Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #79 of 28,963 conditions by registered trial count.
145 US clinical trials · 30 currently recruiting · #79 of 28,963 conditions by registered trial count
Alzheimers Disease: 145 US clinical trials tracked, 30 recruiting.
Alzheimers Disease is the subject of 145 registered US clinical trials on ClinicalTrials.gov, 30 of them currently open to new participants. 25 are in Phase 3-4 (later-stage) and 74 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 8 of these trials.
Open enrollment, early-phase tilt
Alzheimers Disease has 145 registered US clinical trials, 30 of them open to new participants right now, about 21% of the total.
- 30
- recruiting participants now
- 21%
- of trials open to enrollment
- 25
- in Phase 3-4 (later-stage)
- 8
- top sponsor: Eli Lilly and Company
Corpus placement: #79 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Alzheimers Disease on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Alzheimers Disease is recruiting below its size-band peers.
30 of 145 indexed trials (20.7%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Alzheimers Disease trials is spread across many organizations.
Eli Lilly and Company accounts for 8 of 145 trials (5.5%). 86 distinct sponsors appear on at least one study for this condition label.
-
Typical Alzheimers Disease enrolment sits around 107 participants.
Median target enrolment is 107 among the 143 trials that report a genuine target (sentinel values excluded). 66 of those (46.2%) plan for fewer than 100 participants.
-
Alzheimers Disease research is mostly interventional.
119 interventional and 26 observational studies make up this index (82.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
145 total, page 1 of 3
Alzheimer's Prevention Registry: A Program to Accelerate Enrollment Into Studies
Banner Health
NCT02022943
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
Hoffmann-La Roche
NCT07177352
A Postmarketing Study of Lecanemab in South Korean Participants With Alzheimer's Disease
Eisai Korea
NCT06810960
Retinal Imaging in Neurodegenerative Disease
Duke University
NCT03233646
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
GAP Innovations, PBC
NCT06584357
Wake Forest Alzheimer's Disease Clinical Core
Wake Forest University Health Sciences
NCT03140865
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Hoffmann-La Roche
NCT07170150
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Hoffmann-La Roche
NCT07169578
Dominantly Inherited Alzheimer Network (DIAN)
Washington University School of Medicine
NCT00869817
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Bristol-Myers Squibb
NCT06976216
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Bristol-Myers Squibb
NCT06976203
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
Novartis Pharmaceuticals
NCT07094516
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Washington University School of Medicine
NCT06647498
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Washington University School of Medicine
NCT05552157
PET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases
Brigham and Women's Hospital
NCT02649985
Open-label Extension Study in Participants With Early Alzheimer's Disease
GlaxoSmithKline
NCT07105709
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
National Institute of Mental Health (NIMH)
NCT04396873
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
AC Immune
NCT05462106
Tau PET/CT Imaging in the Mismatch Prospective Cohort Study (MPC-TAU)
University of Pennsylvania
NCT05658913
A Multi-Modal Combination Intervention to Promote Cognitive Function in Older Intensive Care Unit Survivors
University of Washington
NCT06411561
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
Douglas Scharre
NCT03019757
University of Central Florida Music Study
University of Central Florida
NCT07306065
TREAD: Time Restricted Eating Intervention for Alzheimer's Disease
University of California, San Diego
NCT06548191
Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy
Massachusetts Institute of Technology
NCT05655195
Pulsed Electromagnetic Field Treatment With Dementia Patients
Herrick Medical
NCT06862557
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
Oregon Health and Science University
NCT05591027
Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study
Cedars-Sinai Medical Center
NCT07224607
Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease
Brigham and Women's Hospital
NCT06489548
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
Mark Tuszynski
NCT05040217
Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease
Emory University
NCT06484244
A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology
Eisai Limited
NCT06043700
A Study of Remternetug (LY3372993) in Participants With Alzheimer's Disease (TRAILRUNNER-ALZ 1)
Eli Lilly and Company
NCT05463731
A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)
Eli Lilly and Company
NCT06653153
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
Eli Lilly and Company
NCT05738486
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
Washington University School of Medicine
NCT01760005
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
GlaxoSmithKline
NCT06079190
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
Hoffmann-La Roche
NCT04639050
Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease
Neurim Pharmaceuticals
NCT05267535
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)
Washington University School of Medicine
NCT05269394
A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer's Disease
Eisai
NCT06602258
Tango for Alzheimer's Disease Patients' Caregivers
Emory University
NCT03269149
DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease
Washington University School of Medicine
NCT06384573
Imaging Dementia-Evidence for Amyloid Scanning (IDEAS) Study
American College of Radiology
NCT02420756
Ginkgo Biloba Prevention Trial in Older Individuals
National Center for Complementary and Integrative Health (NCCIH)
NCT00010803
Observational Study on Costs and Caregiver Burden in Alzheimer's Disease
AstraZeneca
NCT00698165
Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease
Eisai
NCT00478205
Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo
Eli Lilly and Company
NCT00762411
Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil
H. Lundbeck A/S
NCT01955161
Open-Label Extension Study of 23 mg Donepezil SR in Participants With Moderate to Severe Alzheimer's Disease
Eisai
NCT00566501
Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease
GlaxoSmithKline
NCT00428090
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 35 |
| Phase 2 | 39 |
| Phase 3 | 25 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Alzheimers Disease right now
30 recruiting of 145 indexed (21% open).
Phase mix: 25 late (III/IV) vs 74 early (I/II) (early-phase heavy).
Top sponsor: Eli Lilly and Company (8 trials), 9 others listed. 50 shown below, recruiting first. #79 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for Alzheimers Disease?
PlainTrial tracks 145 US clinical trials for Alzheimers Disease, of which 30 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Alzheimers Disease?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.